Smith & Nephew PLC | Cash Flow

Fiscal year is January-December. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
513,084.90
433,632.10
365,884.70
787,074.80
682,547.70
585,718.80
Depreciation, Depletion & Amortization
230,952.20
250,826.40
291,267.80
307,566.90
337,779.60
320,232.90
Other Funds
639.80
6,680.60
9,818.00
18,528.10
18,636.10
64,496.60
Funds from Operations
584,737.60
510,762.70
604,135.20
755,206.40
925,593.70
841,455.10
Changes in Working Capital
30,068.60
95,957.80
70,035.20
125,991.30
79,203.50
141,742.40
Net Operating Cash Flow
554,669.10
414,804.90
674,170.40
629,215.20
846,390.20
699,712.70
Capital Expenditures
217,517.30
227,747.90
234,323.30
290,521.00
291,965.80
Sale of Fixed Assets & Businesses
-
12,146.60
-
254,205.90
-
Purchase/Sale of Investments
4,478.30
110,533.70
17,672.40
1,482.30
6,212.00
Net Investing Cash Flow
260,381.00
1,059,787.10
280,795.30
283,850.90
421,642.10
Cash Dividends Paid - Total
152,901.90
151,832.00
178,033.40
206,773.90
208,879.80
Issuance/Reduction of Debt, Net
49,901.00
789,526.20
147,270.20
126,732.40
114,146.20
Net Financing Cash Flow
318,598.80
612,186.40
371,775.50
359,445.60
337,003.10
Net Change in Cash
26,230.00
37,047.00
17,672.40
14,822.50
90,851.10
Free Cash Flow
337,151.80
233,821.20
475,846.50
392,055.10
607,226.70
Net Assets from Acquisitions
47,342.00
954,719.30
28,799.50
158,600.80
123,464.30
Change in Capital Stock
115,156.20
18,827.20
36,653.90
260,876.00
32,613.20
Exchange Rate Effect
1,919.30
4,251.30
3,927.20
741.10
3,106.00
Other Uses
-
-
-
87,452.80
-

About Smith & Nephew

View Profile
Address
Croxley Park
Watford Herefordshire WD18 8YE
United Kingdom
Employees -
Website http://smith-nephew.com/
Updated 07/08/2019
Smith & Nephew Plc engages in the development, manufacture, marketing, and sale of medical devices. It offers the following products and services: sports medicine joint repair; arthroscopic enabling technologies; trauma and extremities; other surgical businesses; knee and hip implants, and advanced wound care, wound bioactives, and wound devices. It operates through the United Kingdom, United States of America, and Other geographical segments.